Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 6,500 Shares

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 6,500 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $78.69, for a total transaction of $511,485.00. Following the completion of the sale, the insider directly owned 37,793 shares in the company, valued at $2,973,931.17. This trade represents a 14.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Disc Medicine Stock Down 0.6%

Disc Medicine stock opened at $78.63 on Tuesday. The company has a market capitalization of $2.97 billion, a PE ratio of -14.70 and a beta of 0.87. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $99.50. The firm has a 50 day moving average price of $87.26 and a 200 day moving average price of $71.22.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). Research analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Institutional Trading of Disc Medicine

Hedge funds have recently added to or reduced their stakes in the company. MetLife Investment Management LLC grew its holdings in Disc Medicine by 10.9% during the 1st quarter. MetLife Investment Management LLC now owns 13,454 shares of the company’s stock worth $668,000 after acquiring an additional 1,322 shares in the last quarter. Corebridge Financial Inc. lifted its position in shares of Disc Medicine by 14.0% during the 1st quarter. Corebridge Financial Inc. now owns 11,180 shares of the company’s stock worth $555,000 after purchasing an additional 1,371 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Disc Medicine by 22.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock worth $756,000 after purchasing an additional 2,807 shares in the last quarter. Millennium Management LLC grew its stake in shares of Disc Medicine by 1,277.1% during the first quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock worth $5,386,000 after purchasing an additional 100,620 shares in the last quarter. Finally, Zimmer Partners LP increased its holdings in Disc Medicine by 29.6% in the first quarter. Zimmer Partners LP now owns 42,900 shares of the company’s stock valued at $2,130,000 after buying an additional 9,800 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on IRON shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, October 8th. Stifel Nicolaus started coverage on shares of Disc Medicine in a report on Monday, November 3rd. They issued a “buy” rating and a $125.00 price objective for the company. Raymond James Financial reaffirmed a “strong-buy” rating and set a $117.00 target price on shares of Disc Medicine in a research note on Monday, December 8th. Cantor Fitzgerald raised their price target on shares of Disc Medicine from $132.00 to $153.00 and gave the company an “overweight” rating in a research report on Friday, October 17th. Finally, National Bankshares set a $153.00 price target on shares of Disc Medicine in a research note on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $119.00.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.